ReviewCurrent opinion in pediatrics2011
Medical treatment overview: traditional and novel psycho-pharmacological and complementary and alternative medications.
Review in Current opinion in pediatrics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- The Pharmacokinetics, Dosage, Preparation Forms, and Efficacy of Orally Administered Melatonin for Non-Organic Sleep Disorders in Autism Spectrum Disorder During Childhood and Adolescence: A Systematic Review.Children (Basel, Switzerland) · 2025Review
- Unveiling the neuroprotective potential of dietary polysaccharides: a systematic review.Frontiers in nutrition · 2023Review
- Evidence or no evidence for essential fatty acids in the treatment of autism spectrum disorders?Frontiers in nutrition · 2023Review
- Understanding autism spectrum disorders with animal models: applications, insights, and perspectives.Zoological research · 2021Review
- Dietary and Supplement-Based Complementary and Alternative Medicine Use in Pediatric Autism Spectrum Disorder.Nutrients · 2019Article
- Parents' Use of Complementary Health Approaches for Young Children with Autism Spectrum Disorder.Journal of autism and developmental disorders · 2018Article
- Use and Nondisclosure of Complementary Health Approaches Among US Children with Developmental Disabilities.Journal of developmental and behavioral pediatrics : JDBP · 2018Article
- Parent disclosure of complementary health approaches used for children with autism spectrum disorder: Barriers and facilitators.Complementary therapies in medicine · 2017Article
- Prevalence and Predictors of Complementary and Alternative Medicine Use in a Large Insured Sample of Children with Autism Spectrum Disorders.Research in autism spectrum disorders · 2015Article
- Elevated burden for caregivers of children with persistent asthma and a developmental disability.Maternal and child health journal · 2014Article
- Autism spectrum disorder: advances in evidence-based practice.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2014Review
- Translational medicine: Mice and men show the way.Nature · 2012Article
- A review of complementary and alternative treatments for autism spectrum disorders.Autism research and treatment · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
Abstract
purpose of reviewUp to 35% of children and youth with autism spectrum disorder (ASD) receive at least one psychotropic medication. 50-70% of this population also receives biologically based complementary and alternative medicine (CAM). The data evaluating such practices are being reviewed. RECENT
findingsThere are accumulating data to suggest that atypical antipsychotics and stimulants may be useful for the treatment of irritability and hyperactivity in children and youth with ASD. The data for the use of selective serotonin reuptake inhibitors are less promising. New avenues of pharmacologic research targeting molecular targets identified by genomics, animal models and neuropathology are being evaluated. Areas of interest include glutamate/gamma-aminobutyric acid systems, neuropeptides such as oxytocin, and immune dysfunction, among others. In the case of biologically based CAM, a few compounds have been shown to be well tolerated, although efficacy is still being evaluated, such as melatonin, certain vitamins, and omega 3 fatty acids. Others have safety concerns without demonstrated efficacy, such as chelation therapies. SUMMARY: Accumulating data suggest a series of existing medications may be useful in ASD and large randomized clinical trials are necessary to evaluate safety and efficacy of both pharmaceuticals and alternative treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.